Related references
Note: Only part of the references are listed.Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
Kinsie E. Arnst et al.
MEDICINAL RESEARCH REVIEWS (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
Marco Tagliamento et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Jo Lynne Rokita et al.
CELL REPORTS (2019)
Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
Clare E. Weeden et al.
ONCOGENE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Darcy Bates et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Consequences of mitotic slippage for antimicrotubule drug therapy
Bing Cheng et al.
ENDOCRINE-RELATED CANCER (2017)
Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma
Clare E. Weeden et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Larissa Siqueira Penna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Therapeutic management options for stage III non-small cell lung cancer
Stephanie M. Yoon et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
Monique D. Topp et al.
MOLECULAR ONCOLOGY (2014)
Mitosis as an anti-cancer drug target
Anna-Leena Salmela et al.
CHROMOSOMA (2013)
Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
A. Frost et al.
CURRENT ONCOLOGY (2012)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Aurora kinase B/C inhibition impairs malignant glioma growth in vivo
Roberto Jose Diaz et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
Evolution of Resistance to Aurora Kinase B Inhibitors in Leukaemia Cells
Timothy W. Failes et al.
PLOS ONE (2012)
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mitosis-targeted anti-cancer therapies: where they stand
K-S Chan et al.
CELL DEATH & DISEASE (2012)
Metadata matters: access to image data in the real world
Melissa Linkert et al.
JOURNAL OF CELL BIOLOGY (2010)
Still entangled: Assembly of the central spindle by multiple microtubule modulators
Max E. Douglas et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System
Annalisa Canta et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Aurora kinase inhibitors in preclinical and clinical testing
Chun Hei Antonio Cheung et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
How do anti-mitotic drugs kill cancer cells?
Karen E. Gascoigne et al.
JOURNAL OF CELL SCIENCE (2009)
Cancer cells display intra- and interline variation profound following prolonged exposure to antimitotic drugs
Karen E. Gascoigne et al.
CANCER CELL (2008)
Class I β-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions
Tracy Y. E. Liaw et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Synthesis and biological evaluation of analogues of the anti-tumor alkaloid naamidine A
Nicholas Aberle et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions
NM Verrills et al.
CHEMISTRY & BIOLOGY (2003)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
M. Abal et al.
CURRENT CANCER DRUG TARGETS (2003)
A novel microtubule destabilizing entity from orthogonal synthesis of triazine library and zebrafish embryo screening
HS Moon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Synthesis and biological evaluation of myoseverin derivatives: Microtubule assembly inhibitors
YT Chang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Physiochemical aspects of tubulin-interacting antimitotic drugs
JJ Correia et al.
CURRENT PHARMACEUTICAL DESIGN (2001)
Myoseverin, a microtubule-binding molecule with novel cellular effects
GR Rosania et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
